These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36215918)

  • 41. Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile.
    Xu J; Wang A; Wangqin R; Mo J; Chen Z; Dai L; Meng X; Zhao X; Wang Y; Li H; Chen W; Xian Y; Wang Y;
    Ann Neurol; 2019 Sep; 86(3):419-426. PubMed ID: 31237713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.
    Tornio A; Flynn R; Morant S; Velten E; Palmer CNA; MacDonald TM; Doney ASF
    Clin Pharmacol Ther; 2018 Feb; 103(2):281-286. PubMed ID: 28653333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
    Wei YQ; Wang DG; Yang H; Cao H
    PLoS One; 2015; 10(7):e0132561. PubMed ID: 26147597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
    Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
    J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of CYP2C19 Polymorphisms With Clopidogrel Reactivity and Clinical Outcomes in Chronic Ischemic Stroke.
    Tanaka T; Yamagami H; Ihara M; Miyata T; Miyata S; Hamasaki T; Amano S; Fukuma K; Yamamoto H; Nakagawara J; Furui E; Uchiyama S; Hyun B; Yamamoto Y; Manabe Y; Ito Y; Fukunaga R; Abumiya T; Yasaka M; Kitagawa K; Toyoda K; Nagatsuka K
    Circ J; 2019 May; 83(6):1385-1393. PubMed ID: 31006731
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
    Wang Y; Cai H; Zhou G; Zhang Z; Liu X
    J Neurol Sci; 2016 Oct; 369():216-219. PubMed ID: 27653892
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients.
    Li C; Jia W; Li J; Li F; Ma J; Zhou L
    BMC Neurol; 2021 Mar; 21(1):104. PubMed ID: 33685396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis.
    Biswas M; Rahaman S; Biswas TK; Ibrahim B
    Int J Clin Pharm; 2021 Oct; 43(5):1360-1369. PubMed ID: 33774763
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by
    Zhou M; Chen W; Pan Y; Lin Y; Meng X; Zhao X; Liu L; Lin J; Li H; Wang Y; Wang Y
    Aging (Albany NY); 2020 Dec; 13(3):3994-4006. PubMed ID: 33411687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2.
    Yi X; Han Z; Zhou Q; Cheng W; Lin J; Wang C
    Clin Appl Thromb Hemost; 2018 Jan; 24(1):55-62. PubMed ID: 27637911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is
    Ganoci L; Palić J; Trkulja V; Starčević K; Šimičević L; Božina N; Lovrić-Benčić M; Poljaković Z; Božina T
    Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.
    Hokimoto S; Mizobe M; Akasaka T; Arima Y; Kaikita K; Nakagawa K; Ogawa H
    Thromb Res; 2014 Apr; 133(4):599-605. PubMed ID: 24440142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.
    Yi X; Wang Y; Lin J; Cheng W; Zhou Q; Wang C
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):761-768. PubMed ID: 27233747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors associated with clopidogrel resistance and clinical outcomes in ischemic cerebrovascular disease: A retrospective study.
    Wu Y; Shen H; Cai B; Chen C; Yin Q; Zhao Y; Zhou G
    J Stroke Cerebrovasc Dis; 2024 Jun; 33(6):107684. PubMed ID: 38518890
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
    Novkovic M; Matic D; Kusic-Tisma J; Antonijevic N; Radojkovic D; Rakicevic L
    Eur J Clin Pharmacol; 2018 Apr; 74(4):443-451. PubMed ID: 29260275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Correlation between CYP2C19 Gene Polymorphism and Elderly Cerebral Infarction].
    Fan DJ; Li CY; Chen J; Ye ZQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Dec; 40(6):765-768. PubMed ID: 30606386
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
    J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2.
    Watanabe H; Morimoto T; Ogita M; Suwa S; Natsuaki M; Suematsu N; Koeda Y; Morino Y; Nikaido A; Hata Y; Doi M; Hibi K; Kimura K; Yoda S; Kaneko T; Nishida K; Kawai K; Yamaguchi K; Wakatsuki T; Tonoike N; Yamamoto M; Shimizu S; Shimohama T; Ako J; Kimura T;
    Cardiovasc Interv Ther; 2021 Oct; 36(4):403-415. PubMed ID: 33184726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Clopidogrel for Prevention of Stroke Based on
    Meschia JF; Walton RL; Farrugia LP; Ross OA; Elm JJ; Farrant M; Meurer WJ; Lindblad AS; Barsan W; Ching M; Gentile N; Ross M; Nahab F; Easton JD; Kim AS; Zurita KG; Cucchiara B; Johnston SC
    Stroke; 2020 Jul; 51(7):2058-2065. PubMed ID: 32568642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of Insulin Receptor Substrate-1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention.
    Zong J; Tang Y; Wang T; Ullah I; Xu K; Wang J; Chen P; Chen Z; Zhu T; Chen J; Li J; Wang F; Yang L; Fan Y; Shi L; Gong X; Eikelboom JW; Zhao Y; Li C
    J Am Heart Assoc; 2022 Aug; 11(16):e025058. PubMed ID: 35929455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.